Although echoing reports of JAM-A protein upregulation by the in situ stage in adenocarcinomas of the cervix [28] and lung [29], it does not by itself provide evidence of a causal role for JAM-A in disease progression. This evidence concerns the gene F11R and adenocarcinoma.